Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

A crude capsular polysaccharide extract as a potential novel subunit vaccine with cross-protection against the most prevalent serovars of Glaesserella (Haemophilus) parasuis in the Czech Republic

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F19%3AN0000215" target="_blank" >RIV/00027162:_____/19:N0000215 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/62157124:16170/19:43878266

  • Výsledek na webu

    <a href="https://www.agriculturejournals.cz/publicFiles/71_2019-VETMED.pdf" target="_blank" >https://www.agriculturejournals.cz/publicFiles/71_2019-VETMED.pdf</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.17221/71/2019-VETMED" target="_blank" >10.17221/71/2019-VETMED</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    A crude capsular polysaccharide extract as a potential novel subunit vaccine with cross-protection against the most prevalent serovars of Glaesserella (Haemophilus) parasuis in the Czech Republic

  • Popis výsledku v původním jazyce

    Glaesserella (Haemophilus) parasuis is a part of the normal flora of the respiratory tract of pigs. How-ever, under certain conditions it can also induce severe systemic disease with high morbidity and mortality leading to gross economic losses in the pig industry. The most prevalent serovars in pig herds in the Czech Republic are the virulent serovars 1, 4, 5 and 13. The currently available commercial vaccines are inactivated vaccines with certain limitations, such as no or poor cross-serovar protection. Therefore, the aim of the present study was to construct a subunit vaccine with a crude capsular polysaccharide extract (cCPS) isolated from G. parasuis CAPM 6475 (serovar 5) and evaluate its immunogenicity in a mouse model. Mice were immunised subcutane¬ously with two doses of the constructed vaccine in a 14-day interval and challenged intraperitoneally with various G. parasuis strains (serovars 1, 4, 5, 13) at 21 days after the second immunisation. The results of the ELISA test showed that the boost dose of the vaccine induced the production of IgG antibodies in high levels. On the basis of the death cases, the pathological findings and the bacterial isolation, the mice immunised with the cCPS were partially protected against the challenge with the homologous serovar 5 as well as with heterologous serovars 1, 4 and 13 of G. parasuis. The cross-reaction of the mixed serum from the immunised mice with the tested serovars was seen in the western-blotting also. Moreover, the most abundant protein found in the cCPS by mass spectrometry was catalase, a protein of molecular weight 55 kDa that may correspond to the strongest reaction seen in the western-blotting. Our findings indicated that the crude capsular polysaccharide extract may provide an effective immunogenicity in preventing a G. parasuis infection caused by the most prevalent serovars in the Czech Republic. However, the evaluation of the efficacy needs to be performed in pigs before any conclusions can be drawn.

  • Název v anglickém jazyce

    A crude capsular polysaccharide extract as a potential novel subunit vaccine with cross-protection against the most prevalent serovars of Glaesserella (Haemophilus) parasuis in the Czech Republic

  • Popis výsledku anglicky

    Glaesserella (Haemophilus) parasuis is a part of the normal flora of the respiratory tract of pigs. How-ever, under certain conditions it can also induce severe systemic disease with high morbidity and mortality leading to gross economic losses in the pig industry. The most prevalent serovars in pig herds in the Czech Republic are the virulent serovars 1, 4, 5 and 13. The currently available commercial vaccines are inactivated vaccines with certain limitations, such as no or poor cross-serovar protection. Therefore, the aim of the present study was to construct a subunit vaccine with a crude capsular polysaccharide extract (cCPS) isolated from G. parasuis CAPM 6475 (serovar 5) and evaluate its immunogenicity in a mouse model. Mice were immunised subcutane¬ously with two doses of the constructed vaccine in a 14-day interval and challenged intraperitoneally with various G. parasuis strains (serovars 1, 4, 5, 13) at 21 days after the second immunisation. The results of the ELISA test showed that the boost dose of the vaccine induced the production of IgG antibodies in high levels. On the basis of the death cases, the pathological findings and the bacterial isolation, the mice immunised with the cCPS were partially protected against the challenge with the homologous serovar 5 as well as with heterologous serovars 1, 4 and 13 of G. parasuis. The cross-reaction of the mixed serum from the immunised mice with the tested serovars was seen in the western-blotting also. Moreover, the most abundant protein found in the cCPS by mass spectrometry was catalase, a protein of molecular weight 55 kDa that may correspond to the strongest reaction seen in the western-blotting. Our findings indicated that the crude capsular polysaccharide extract may provide an effective immunogenicity in preventing a G. parasuis infection caused by the most prevalent serovars in the Czech Republic. However, the evaluation of the efficacy needs to be performed in pigs before any conclusions can be drawn.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    40301 - Veterinary science

Návaznosti výsledku

  • Projekt

    Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

  • Návaznosti

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Ostatní

  • Rok uplatnění

    2019

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Veterinární medicína

  • ISSN

    0375-8427

  • e-ISSN

  • Svazek periodika

    64

  • Číslo periodika v rámci svazku

    9

  • Stát vydavatele periodika

    CZ - Česká republika

  • Počet stran výsledku

    8

  • Strana od-do

    392-399

  • Kód UT WoS článku

    000488083000003

  • EID výsledku v databázi Scopus